PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid‐lowering effects
出版年份 2019 全文链接
标题
PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid‐lowering effects
作者
关键词
-
出版物
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-09-27
DOI
10.1111/jcmm.14586
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection
- (2018) Susana Cadenas FREE RADICAL BIOLOGY AND MEDICINE
- PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol
- (2018) Zhao-Peng Liu et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Humanin exerts cardioprotection against cardiac ischemia/reperfusion injury through attenuation of mitochondrial dysfunction
- (2016) Savitree Thummasorn et al. Cardiovascular Therapeutics
- Relationship Between Infarct Size and Outcomes Following Primary PCI
- (2016) Gregg W. Stone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?
- (2015) Miguel Cainzos-Achirica et al. ANNALS OF INTERNAL MEDICINE
- Update of Clinical Trials of Anti-PCSK9 Antibodies
- (2015) Na-Qiong Wu et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Systematic review/Meta-analysis The incidence of acute myocardial infarction in relation to overweight and obesity: a meta-analysis
- (2014) Jun Zhu et al. Archives of Medical Science
- Mdivi-1 Protects Against Ischemic Brain Injury via Elevating Extracellular Adenosine in a cAMP/CREB-CD39-Dependent Manner
- (2014) Mei Cui et al. MOLECULAR NEUROBIOLOGY
- Combined Vildagliptin and Metformin Exert Better Cardioprotection than Monotherapy against Ischemia-Reperfusion Injury in Obese-Insulin Resistant Rats
- (2014) Nattayaporn Apaijai et al. PLoS One
- Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission
- (2013) Willard W. Sharp et al. FASEB JOURNAL
- Myocardial ischemia-reperfusion injury: a neglected therapeutic target
- (2013) Derek J. Hausenloy et al. JOURNAL OF CLINICAL INVESTIGATION
- The Lambeth Conventions (II): Guidelines for the study of animal and human ventricular and supraventricular arrhythmias
- (2013) Michael J. Curtis et al. PHARMACOLOGY & THERAPEUTICS
- Acute Inhibition of Excessive Mitochondrial Fission After Myocardial Infarction Prevents Long‐term Cardiac Dysfunction
- (2013) Marie‐Hélène Disatnik et al. Journal of the American Heart Association
- Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease
- (2012) Tetsuya Tobaru et al. HEART AND VESSELS
- Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury
- (2010) Sang-Bing Ong et al. CIRCULATION
- Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis
- (2009) G. Dewson et al. JOURNAL OF CELL SCIENCE
- Comparison of cumulative planimetry versus manual dissection to assess experimental infarct size in isolated hearts
- (2009) Matthias L. Riess et al. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
- Plasma PCSK9 preferentially reduces liver LDL receptors in mice
- (2008) Aldo Grefhorst et al. JOURNAL OF LIPID RESEARCH
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started